Versatope Therapeutics Inc.
Lowell, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 110 Canal St Fl 4, Lowell, MA 01852, USA
- Website
- versatope.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $955,166 |
| FY2024 | $3,608,426 |
| FY2023 | $4,002,853 |
Contract awards
Grant awards
Similar vendors
About the company
Versatope Therapeutics Inc. is a for-profit biotechnology company that delivers immunity through customized nano-sized vesicles using synthetic biology, revolutionizing immunotherapy for infectious diseases and cancer. It was registered in SAM.gov in February 2017 as a corporate entity and for-profit organization.
Versatope Therapeutics Inc. was awarded a $21,256,273 definitive contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases in September 2019 to advance development of recombinant outer membrane vesicle-based vaccines as part of the Broad Agency Announcement 2018 program. This cost-plus-fixed-fee contract supports research to establish and improve biomedical knowledge on infectious diseases such as malaria through April 2027. No set-aside designation was applied to this award made under the NIH-NIAID-BAA2018 vehicle to the for-profit prime contractor located in Lowell, Massachusetts.
The National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,762 Project Grant in December 2023 to Versatope Therapeutics Inc. under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will advance the development of Versatope's recombinant outer membrane vesicle (ROMV) platform as a novel adjuvant for a malaria vaccine. Key deliverables include preclinical studies, toxicology assessments, and manufacturing process development to ready the ROMV-based malaria vaccine candidate for eventual clinical evaluation. Additionally, Versatope received a $299,928 Project Grant from NIH NIAID in August 2020 for a novel C. difficile vaccine using a nano-vesicle delivery system, and a $45,808 Cooperative Agreement from CDC in September 2019 for a multivalent influenza vaccine using exosomes from probiotic E. coli.
Quick answers
Is Versatope Therapeutics Inc. registered in SAM.gov?
Yes. Versatope Therapeutics Inc.'s SAM.gov registration is active through September 16, 2027.
What is Versatope Therapeutics Inc.'s CAGE code?
Versatope Therapeutics Inc.'s CAGE code is 7TEE7, and its Unique Entity ID (UEI) is VSMPM3EGYYA6.
How much has Versatope Therapeutics Inc. received in federal contracts?
Federal contracts obligated $955,166 to Versatope Therapeutics Inc. in fiscal year 2025 and $8,566,445 in fiscal years 2023 through 2027.
What is Versatope Therapeutics Inc.'s most recent federal award?
Versatope Therapeutics Inc.'s most recent federal grant award is Recombinant outer membrane vesicles as a novel adjuvant for a malaria vaccine (R44AI181242), from National Institute of Allergy and Infectious Diseases (NIH), on December 8, 2023.
On GovTribe
See Versatope Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors